You searched for "requirements"
Optegra celebrates 15th anniversary and announces expansion plans
Specialist eye hospital Optegra marks its 15th anniversary this month, having opened its first UK hospital in Guildford in 2008.Preview: UKISCRS 48th Annual Congress 2024
One of the biggest UKISCRS events is upon us, and we’ll all by making our way down there in the next several weeks or so. Not only is it the 75th anniversary of the IOL, but it is also the...What's trending Apr/May 2022
A round-up of the eye-related hot topics that have been trending over the last few weeks. #ArgusI #ArgusII #bioniceye #retinitispigmentosa #SecondSight Remember Argus I & Argus II? Its star burned bright, touted as the future of treatment for retinitis pigmentosa....My top five: Emerging alternatives to manage and treat nAMD
Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...Non-infectious Uveitis: Well Known, Weird and Wonderful meets You, Me and the Balloons
Installation view from Manchester International Festival 2023 exhibition Yayoi Kusama: You, Me and the Balloons at Aviva Studios. Images © David Levene. On an uncharacteristically salubrious 5 July 2023, the date of the 75th Anniversary of the UK’s NHS, a...Part 2: Good news, bad news at the international conference
In the second instalment of this two-part article (click here for Part 1), our editor Peter Cackett presents the ‘good news’ and ‘bad news’ from an international conference experience. Readers will remember that in the last issue I left you...My Top Five: Emerging alternatives to manage and treat nAMD
Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...From paper to pocket: Standardising eyecare with the Malawi Eye Care App
Malawi’s population is mostly rural; the government and Christian Health Association of Malawi (CHAM) together deliver about 80% of healthcare services through local district and community health facilities [1]. However, ophthalmology specialist services are only concentrated in the central hospitals....
Fingolimod: ocular adverse effects
In this article the authors review the ocular side-effects of Fingolimod which is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). Fingolimod-associated macular oedema (FAME) is the most common ocular side-effect linked to this drug....
Visual performance of new multifocal IOL
Multifocal IOLs (MIOLs) keep evolving to try and get the best outcome in terms of vision and reduction of side-effects. This prospective interventional study was carried out on 34 eyes of 17 patients (11 women (65%) and six men (35%))...
Intravitreal aflibercept for retinal angiomatous proliferation (RAP)
In this prospective study the authors present the visual and anatomical outcome of patients with RAP lesions who were treated with intravitreal aflibercept. The study cohort of 46 patients reached study completion at week 96. They were all Caucasians, with...
